We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Pioglitazone (Actos) — thiazolidinedione PPAR-gamma agonist
An oral thiazolidinedione (Actos) diabetes drug that improves insulin sensitivity via PPAR-gamma. It drew geroscience interest after reducing recurrent stroke/MI in insulin-resistant non-diabetics (IRIS) and improving NASH liver histology — but weight gain, fluid retention / heart-failure risk, fracture risk, and a debated bladder-cancer signal keep enthusiasm in check. Prescription drug, not a supplement.
Prescription medication — not a dietary supplement
Pioglitazone (Actos) is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Pioglitazone (Actos) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2005–2026 with a typical study size of 5,238 participants.
Based on 66 studies · 19 meta-analyses · 45 RCTs · 33,658 total participants
Confidence
High confidenceBy outcome
Pioglitazone has strong randomized human evidence for improving insulin sensitivity, reducing recurrent stroke/MI in insulin-resistant non-diabetics (IRIS), and improving NASH liver histology — but general longevity is unproven, and weight gain, fluid retention / heart-failure risk, fracture risk (esp. women), and a debated bladder-cancer signal keep the metabolic-longevity use at moderate.
83 rigorous studies
59 randomized trials · 21 meta-analyses · 3 systematic reviews
Our evidence rating for Pioglitazone (Actos) is accountable to this entire body of rigorous research indexed in PubMed — not a hand-picked subset.
PubMed · as of Jul 2026
51 trials ongoing or recruiting · 385 completed on ClinicalTrials.gov
161 of the completed trials have posted results
Registered trials show research momentum for Pioglitazone (Actos), not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Aug 2026
Pioglitazone is an oral thiazolidinedione (TZD) — a PPAR-gamma agonist — approved for type 2 diabetes, where it improves insulin sensitivity by reprogramming adipocyte metabolism, lowering circulating free fatty acids, and redistributing fat away from liver and muscle.
That insulin-sensitizing, anti-inflammatory profile is why it appears on the metabolic-longevity map.
The strongest signal comes from the IRIS trial (NEJM 2016): in patients with insulin resistance but without diabetes who had a recent stroke or TIA, pioglitazone reduced recurrent stroke and myocardial infarction (and lowered progression to diabetes) versus placebo.
In type 2 diabetes, the large PROactive trial missed its primary composite endpoint but showed a significant reduction in a secondary composite of death, MI, and stroke.
Pioglitazone is also one of the few agents with randomized histologic evidence in non-alcoholic steatohepatitis (NASH/MASH): both Belfort (NEJM 2006) and Cusi's long-term trial (Ann Intern Med 2016) showed improved liver histology and NASH resolution.
The honest counterweight is real and well-documented: pioglitazone causes weight gain and fluid retention, raises heart-failure risk (it is contraindicated in symptomatic heart failure), increases bone-fracture risk — especially in women, where a meta-analysis put the odds ratio near 1.7 alongside reduced bone mineral density — and carries a long-debated, probably small bladder-cancer signal that some cohorts (e.g. a propensity-matched study) failed to confirm.
The score reflects genuinely strong human outcome and histologic data for insulin sensitivity, secondary cardiovascular prevention, and NASH, set against weight/edema/heart-failure/fracture harms and an unproven general-longevity claim.
Pioglitazone is a prescription drug; any off-label metabolic-longevity use is clinician-directed and not an approved or self-administered regimen.
Activates the nuclear receptor PPAR-gamma, reprogramming adipocyte gene expression and lipid storage to improve whole-body insulin sensitivity.
Lowers circulating free fatty acids and redistributes fat away from liver and muscle, reducing insulin resistance independent of insulin secretion.
Shifts fat toward subcutaneous depots and dampens metabolic inflammation — the proposed basis for its NASH and vascular benefits.
How Pioglitazone (Actos) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Avoid — contraindicated in symptomatic heart failure; fluid retention can precipitate decompensation.
Caution — meta-analysis shows higher fracture risk in women; weigh against bone health.
Avoid pending the debated bladder-cancer signal.
Combined use increases fluid retention, weight gain, and heart-failure risk.
Markedly raises pioglitazone exposure; the dose should be reduced.
Additive hypoglycemia risk when combined.
Tip: Largely from fat gain and fluid retention; monitor weight and diet.
Tip: Can precipitate or worsen heart failure; report rapid weight gain, swelling, or shortness of breath.
Tip: Associated with lower BMD; weigh against fracture-risk factors, particularly in postmenopausal women.
Tip: Signal is small and not confirmed in all cohorts; avoid in active/prior bladder cancer and investigate unexplained hematuria.
Pioglitazone (Actos) has an evidence score of 4/10 — emerging evidence based on 33 indexed studies, including 1 meta-analysis. An oral thiazolidinedione (Actos) diabetes drug that improves insulin sensitivity via PPAR-gamma. It drew geroscience interest after reducing recurrent stroke/MI in insulin-resistant non-diabetics (IRIS) and improving NASH liver histology — but weight gain, fluid retention / heart-failure risk, fracture risk, and a debated bladder-cancer signal keep enthusiasm in check. Prescription drug, not a supplement. Representative study: PMID 25173606.
The commonly studied dose of Pioglitazone (Actos) is Off-label metabolic use mirrors diabetes dosing (e.g. 15–45 mg once daily) under a clinician. A prescription drug; not an approved longevity regimen.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take Pioglitazone (Actos) is in the morning. It can be taken on an empty stomach. Taken once daily without regard to meals; effects build over weeks.
Pioglitazone (Actos) should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are weight gain, fluid retention / edema, bone fracture (especially women). Use caution if any of these apply to you: Symptomatic heart failure (NYHA III–IV); Active or history of bladder cancer; Active liver disease / significant hepatic impairment.
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism — comparable to metformin in some trials.
Alpha Lipoic Acid
Likely helpsUniversal antioxidant that works in both water and fat, supporting blood sugar control, nerve health, and cellular energy.
Canagliflozin
Mostly mechanism / observationalAn SGLT2-inhibitor diabetes drug (Invokana) that lowers glucose by excreting it in urine. It extended lifespan in male mice in the NIA aging program, and the SGLT2 class has strong proven cardiovascular, kidney, and heart-failure benefits in humans. Longevity benefit itself is unproven; carries genital-infection and (rarely) ketoacidosis risks. Prescription drug, not a supplement.
Empagliflozin
Mostly mechanism / observationalAn SGLT2-inhibitor diabetes drug (Jardiance) with the strongest human outcome evidence of its class — it cuts cardiovascular death, heart-failure hospitalization, and kidney-disease progression even in non-diabetics. The most widely used SGLT2 for off-label 'longevity,' though longevity itself is unproven (the lifespan data are for sibling canagliflozin in mice). A prescription drug, not a supplement.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 66 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research